Publications by authors named "Lisa Rimsza"

100Publications

Frequent expression of activation induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV.

AIDS 2020 Aug 7. Epub 2020 Aug 7.

Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000002653DOI Listing
August 2020

Primary Pulmonary B-cell Lymphoma.

Semin Diagn Pathol 2020 May 19. Epub 2020 May 19.

Mayo Clinic Arizona, Division of Hematopathology, Department of Laboratory Medicine and Pathology, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semdp.2020.04.002DOI Listing
May 2020

PMBL: flying under the immune radar.

Authors:
Lisa M Rimsza

Blood 2019 09;134(10):788-789

Mayo Clinic Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019002493DOI Listing
September 2019

Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma.

Leuk Lymphoma 2019 12 27;60(14):3581-3583. Epub 2019 Jun 27.

Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1633637DOI Listing
December 2019

Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature.

Int J Cancer 2019 12 3;145(11):3078-3088. Epub 2019 Jun 3.

Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32381DOI Listing
December 2019

Profiling of lymphoma from formalin-fixed paraffin-embedded tissue.

Semin Hematol 2019 01 28;56(1):46-51. Epub 2018 May 28.

Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2018.05.003DOI Listing
January 2019

Genomics of aggressive B-cell lymphoma.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):69-74

Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.69DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245962PMC
November 2018

Dissecting aggressive B-cell lymphoma through genomic analysis - What is clinically relevant?

Best Pract Res Clin Haematol 2018 09 7;31(3):187-198. Epub 2018 Jul 7.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216926183004
Publisher Site
http://dx.doi.org/10.1016/j.beha.2018.07.003DOI Listing
September 2018

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

N Engl J Med 2018 04;378(15):1396-1407

From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick (B.T., J.S., Y.Z., D.R.S.) - all in Maryland; the Department of Pathology, City of Hope National Medical Center, Duarte, CA (W.C.C.); the BC Cancer Agency, Vancouver, BC (R.D.G., J.M.C.), and the University Health Network, Laboratory Medicine Program, Toronto General Hospital and University of Toronto, Toronto (J.D.) - both in Canada; the Hospital Clinic of Barcelona, University of Barcelona, Institute for Biomedical Research August Pi I Sunyer, Barcelona (E.C., A.L.-G.); the Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg (A.R.), and the Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart (G.O.) - all in Germany; the Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ (L.M.R.); the National Cancer Centre of Singapore, Singapore (K.T.K.W.); Memorial Sloan Kettering Cancer Center (A.D.Z.) and Weill Cornell Medicine (J.P.L.) - both in New York; the Department of Medicine, Washington University School of Medicine, St. Louis (N.L.B.); and the Alliance for Clinical Trials in Oncology, Chicago (A.D.Z., J.P.L., N.L.B.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1801445
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1801445DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010183PMC
April 2018

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

J Clin Oncol 2018 03 22;36(7):697-703. Epub 2018 Jan 22.

Mazyar Shadman, Ajay K. Gopal, David G. Maloney, and Oliver W. Press, University of Washington and Fred Hutchinson Cancer Research Center; Hongli Li and Michael LeBlanc, SWOG Statistical Center, Seattle, WA; Lisa Rimsza, Mayo Clinic Arizona, Scottsdale; Catherine M. Spier, University of Arizona, Tucson, AZ; John P. Leonard, Weill Cornell Medical College, New York; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; Mark S. Kaminski, University of Michigan Health System, Ann Arbor, MI; Rita M. Braziel, Oregon Health & Science University, Portland, OR; Bruce D. Cheson, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC; Shaker Dakhil, University of Kansas School of Medicine-Wichita, Wichita, KS; Sonali M. Smith, University of Chicago Medicine, Chicago, IL; and Richard I. Fisher, Fox Chase Cancer Center and Temple University School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.5083
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.5083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553811PMC
March 2018

The clinicopathologic spectrum of mature aggressive B cell lymphomas.

Virchows Arch 2017 Oct 26;471(4):453-466. Epub 2017 Aug 26.

Institute of Pathology and Neuropathology and Comprehensive Cancer Center, University Hospital Tübingen, Liebermeisterstrasse 8, 72076, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-017-2199-7DOI Listing
October 2017

Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.

Virchows Arch 2017 Oct 10;471(4):467-489. Epub 2017 Jul 10.

Institute of Pathology and Neuropathology and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-017-2176-1DOI Listing
October 2017

Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth.

J Med Chem 2017 08 25;60(15):6587-6597. Epub 2017 Jul 25.

Department of Pathology, University of Arizona , 1501 North Campbell Avenue, Tucson, Arizona 85724, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.7b00298DOI Listing
August 2017

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

J Clin Oncol 2017 May 14;35(15):1668-1677. Epub 2017 Mar 14.

David W. Scott, Pau Abrisqueta, Graham W. Slack, Anja Mottok, Diego Villa, Merrill Boyle, Fong Chun Chan, Christian Steidl, Joseph M. Connors, and Randy D. Gascoyne, BC Cancer Agency; Anja Mottok, Christian Steidl, and Randy D. Gascoyne, University of British Columbia, Vancouver, British Columbia; Jan Delabie, University of Toronto, Toronto, Ontario, Canada; Pau Abrisqueta, Vall d'Hebron University Hospital; Pedro Jares, Cristina Royo, Guillem Clot, Magda Pinyol, and Elias Campo, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; George W. Wright, Elaine S. Jaffe, and Louis M. Staudt, National Institutes of Health, Bethesda, MD; Hilka Rauert-Wunderlich and Andreas Rosenwald, University of Würzburg, Würzburg; German Ott, Robert Bosch Hospital and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Rita M. Braziel, Oregon Health & Sciences University, Portland, OR; Wing C. Chan and Dennis D. Weisenburger, City of Hope, Duarte, CA; James R. Cook, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Timothy C. Greiner and Kai Fu, University of Nebraska Medical Center, Omaha, NE; Erlend B. Smeland and Harald Holte, Oslo University Hospital, Oslo, Norway; and Lisa M. Rimsza, Mayo Clinic, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455765PMC
May 2017

General Biomarker Recommendations for Lymphoma.

J Natl Cancer Inst 2016 12 16;108(12). Epub 2016 Dec 16.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ (LR), Department of Pathology and Laboratory Medicine, University of North Carolina Medical School, Chapel Hill, NC (YF), Center for Cancer Research, National Cancer Institute, Bethesda, MD (LMS), Department of Medicine, Weill Cornell Medical College, New York, NY (AM), Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada (RG), Clinical Cancer Research Unit, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada (MC), Coordinating Center for Clinical Trials, National Cancer Institute, Bethesda, MD (LB), Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE (KF), Department of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH (ED), Department of Pathology, City of Hope Medical Center, Duarte, CA (JWCC), Biometrics Research Branch, National Cancer Institute, Bethesda, MD (LM), Department of Medicine, Weill Cornell Medicine, New York, NY (JPL), Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK), Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL), Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF), Department of Radiology, Mount Sinai Medical Center New York, NY (LK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080362PMC
December 2016

Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.

Virchows Arch 2017 Jan 25;470(1):113-117. Epub 2016 Nov 25.

Department of Pathology, University of Arizona, P.O. Box 24-5043, 1501 N Campbell Ave, Tucson, AZ, 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-016-2041-7DOI Listing
January 2017

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

J Clin Oncol 2016 06 11;34(17):2020-7. Epub 2016 Apr 11.

Oliver W. Press, Fred Hutchinson Cancer Research Center, and the University of Washington; Hongli Li and Michael LeBlanc, Fred Hutchinson Cancer Research Center, Seattle, WA; Heiko Schöder, David J. Straus, Craig H. Moskowitz, and Ariela Noy, Memorial Sloan Kettering Cancer Center; John P. Leonard, Weill Cornell Medical College and New York Presbyterian Hospital, New York City; Paul M. Barr and Jonathan W. Friedberg, University of Rochester Medical Center, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett and Brad S. Kahl, Washington University School of Medicine, St. Louis, MO; Andrew M. Evens, Tufts Medical Center; Ann S. LaCasce, Dana-Farber Cancer Institute, Boston, MA; Erik S. Mittra, Stanford University Medical Center, Stanford, CA; John W. Sweetenham, Huntsman Cancer Hospital, Salt Lake City, UT; Michelle A. Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Michael V. Knopp, The Ohio State University, Columbus; Eric D. Hsi, Cleveland Clinic Foundation; James R. Cook, Cleveland Clinic, Cleveland, OH; Mary Jo Lechowicz, Winship Cancer Institute of Emory University, Atlanta, GA; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, BC; Bruce D. Cheson, Georgetown University Hospital, Washington DC; and Richard I. Fisher, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966513PMC
June 2016

Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.

Cell Rep 2015 Nov 5;13(7):1418-1431. Epub 2015 Nov 5.

Centre for Lymphoid Cancer, Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.10.008DOI Listing
November 2015

Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.

Proc Natl Acad Sci U S A 2015 Nov 19;112(44):13447-54. Epub 2015 Oct 19.

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1514944112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640740PMC
November 2015

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.

J Clin Oncol 2015 Sep 3;33(26):2848-56. Epub 2015 Aug 3.

David W. Scott, Anja Mottok, Daisuke Ennishi, Pedro Farinha, Susana Ben-Neriah, Robert Kridel, Garrett S. Barry, Christoffer Hother, Pau Abrisqueta, Merrill Boyle, Barbara Meissner, Adele Telenius, Kerry J. Savage, Laurie H. Sehn, Graham W. Slack, Christian Steidl, Joseph M. Connors, and Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; George W. Wright and Louis M. Staudt, National Cancer Institute, Bethesda, MD; and Lisa M. Rimsza, University of Arizona, Tucson, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.2383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554747PMC
September 2015

Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.

Am J Surg Pathol 2015 Oct;39(10):1322-30

*Department of Pathology and Microbiology ¶Department of Biostatistics, College of Public Health ##Department of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE †Metabolism Branch **Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD ∥Department of Pathology, City of Hope National Medical Center, Duarte, CA #Department of Pathology, University of Arizona, Tucson, AZ §§Department of Clinical Pathology, Oregon Health and Science University, Portland, OR ∥∥Department of Molecular Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH ‡Institute of Pathology, Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg ¶¶Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany §British Columbia Cancer Agency, Centre for Lymphoid Cancer, University of British Columbia, Vancouver, BC, Canada ††Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain ‡‡Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000473DOI Listing
October 2015

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.

Cancer Res 2015 Jul 27;75(14):2916-27. Epub 2015 May 27.

BIO5 Institute, University of Arizona, Tucson, Arizona. Department of Medicine, University of Arizona, Tucson, Arizona. Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506255PMC
July 2015

Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String".

Authors:
Lisa M Rimsza

Clin Cancer Res 2015 May 31;21(10):2204-6. Epub 2015 Mar 31.

Department of Pathology, University of Arizona, Tucson, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433835PMC
May 2015

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

J Clin Oncol 2015 May 30;33(13):1482-90. Epub 2015 Mar 30.

Jennifer L. Kelly and Jonathan W. Friedberg, James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard Lyon-1, Pierre Benite; Pauline Brice, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris; Olivier Casasnovas, Centre Hospitalo-Universitaire de Dijon, Dijon; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux 2, Bordeaux; Corinne Haioun, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Créteil; Luc Xerri, Institut Paoli Calmettes, Marseille; Hervé Tilly, Centre Henri Becquerel, Rouen, France; Bryan Goldman, Oliver Press, and Michael LeBlanc, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Richard I. Fisher, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA; and Lisa Rimsza, University of Arizona, Tucson, AZ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/03/30/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.5092
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.5092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404425PMC
May 2015

Indolent lymphoma: follicular lymphoma and the microenvironment-insights from gene expression profiling.

Hematology Am Soc Hematol Educ Program 2014 Dec 18;2014(1):163-8. Epub 2014 Nov 18.

Department of Pathology, University of Arizona, Tucson, AZ.

View Article

Download full-text PDF

Source
http://www.asheducationbook.org/cgi/doi/10.1182/asheducation
Publisher Site
http://dx.doi.org/10.1182/asheducation-2014.1.163DOI Listing
December 2014

Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.

Nature 2014 Dec 28;516(7530):254-8. Epub 2014 Sep 28.

1] Department of Microbiology and Immunology, University of California, San Francisco, California, 94143, USA [2] Howard Hughes Medical Institute, University of California, San Francisco, California 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature13765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267955PMC
December 2014

Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.

Am J Surg Pathol 2014 Apr;38(4):494-501

*Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH †SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA ‡University of Arizona, Tucson, AZ §Fox Chase Cancer Center, Philadelphia, PA ∥Loyola University Medical Center, Maywood, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955880PMC
April 2014

Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.

Nat Genet 2014 Apr 16;46(4):329-35. Epub 2014 Feb 16.

1] Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada. [2] Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2900DOI Listing
April 2014

Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.

Cancer Discov 2014 Apr 3;4(4):480-93. Epub 2014 Feb 3.

1Lymphoid Malignancies Branch, 2Laboratory of Pathology, 3Experimental Immunology Branch, Center for Cancer Research; 4Biometric Research Branch, DCTD, National Cancer Institute; 5Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; 6Department of Pathology, University of Arizona, Tucson, Arizona; 7Oregon Health and Science University, Portland, Oregon; 8Cleveland Clinic Pathology and Laboratory Medicine Institute, Cleveland, Ohio; 9Department of Pathology, City of Hope National Medical Center, Duarte, California; 10Departments of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska; 11Department of Pathology, University of Würzburg, Würzburg; 12Department of Clinical Pathology, Robert-Bosch-Krankenhaus; 13Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany; 14British Columbia Cancer Agency, Vancouver, British Columbia, Canada; 15Hospital Clinic, University of Barcelona, Barcelona, Spain; 16Pathology Clinic, 17Institute for Cancer Research, Rikshospitalet University Hospital; 18Center for Cancer Biomedicine, Faculty Division of the Norwegian Radium Hospital, University of Oslo, Oslo, Norway; and 19Department of Molecular and Cellular Physiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-13-0915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992927PMC
April 2014

Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.

J Clin Oncol 2013 Dec 12;31(36):4520-8. Epub 2013 Nov 12.

Xin Huang, Bin Meng, Wenfeng Cao, and Kai Fu, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin; Chengfeng Bi, West China Hospital, West China School of Medicine of Sichuan University, Chengdu, China; Xin Huang, Bin Meng, Javeed Iqbal, Anamarija M. Perry, Wenfeng Cao, Lynette M. Smith, Chengfeng Bi, Chunsun Jiang, Timothy C. Greiner, Dennis D. Weisenburger, James O. Armitage, Julie M. Vose, Timothy W. McKeithan, Wing C. Chan, and Kai Fu, University of Nebraska Medical Center, Omaha, NE; B. Belinda Ding and B. Hilda Ye, Albert Einstein College of Medicine, Bronx, NY; Lisa Rimsza, University of Arizona, Tucson, AZ; Andreas Rosenwald, University of Würzburg, Würzburg, Germany; German Ott and Jan Delabie, Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; Elias Campo, Hospital Clinic, University of Barcelona, Barcelona, Spain; Rita M. Braziel, Oregon Health and Science University, Portland, OR; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; James R. Cook and Raymond R. Tubbs, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Elaine S. Jaffe and Louis M. Staudt, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.6004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871513PMC
December 2013

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

N Engl J Med 2013 Oct;369(18):1681-90

From Loyola University Medical Center, Maywood, IL (P.J.S., K.P.B.); Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle (J.M.U., M.L.); Cleveland Clinic, Cleveland (J.R.C., R.R.T.); University of Rochester, Rochester, NY (L.S.C., J.W.F., R.I.F.); Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS (S.C.), University of Calgary-Tom Baker Cancer Centre, Calgary, AB (D.A.S.), and Margaret and Charles Juravinski Cancer Centre, Hamilton, ON (D.M.) - all in Canada; University of North Carolina at Chapel Hill, Chapel Hill (T.C.S.); Ohio State University Medical Center, Columbus (P.P.); Northwestern University, Chicago (J.N.W.); University of Wisconsin, Madison (B.S.K.); University of Arizona, Tucson (T.P.M., L.M.R.); Louisiana State University Health Sciences Center, Shreveport (G.M.M.); City of Hope Medical Center, Duarte, CA (S.J.F.); and Fox Chase Cancer Center-Temple Health, Temple University School of Medicine, Philadelphia (R.I.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1301077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418PMC
October 2013

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Clin Cancer Res 2013 Dec 15;19(23):6624-32. Epub 2013 Oct 15.

Authors' Affiliations: Clinical Research Division; SWOG Statistical Center, Fred Hutchinson Cancer Research Center; Medical Oncology, University of Washington Medical Center, Seattle, Washington; Department of Pathology; Arizona Cancer Center, University of Arizona, Tucson, Arizona; James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester; Roswell Park Cancer Institute, Buffalo, New York; Cancer and Leukemia Group B; University of Michigan, Ann Arbor, Michigan; Department of Pathology, Oregon Health and Science University, Portland, Oregon; Georgetown University Hospital, Washington; Wichita Community Clinical Oncology Program, Wichita, Kansas; and Fox Chase Cancer Center-Temple Health, Temple University, Philadelphia PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872052PMC
December 2013

Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma.

Cancer Genet 2013 Jul-Aug;206(7-8):257-65. Epub 2013 Sep 27.

Department of Medicine, Division of Hematology-Oncology, University of Arizona, Tucson, AZ, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergen.2013.07.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485451PMC
December 2013

Developmental differences in megakaryocyte size in infants and children.

Am J Clin Pathol 2012 Jul;138(1):140-5

Department of Pathology, Box 5403, 1501 N Campbell Ave, Tucson, AZ 85724, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1309/AJCP4EMTJYA0VGYEDOI Listing
July 2012